Hematopoietic Stem Cell Transplantation for Children With Inborn Errors of Metabolism: Single Center Experience Over Two Decades
Related Experiment Video
Updated: Sep 6, 2025

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
Published on: December 8, 2023
Venkateswaran Vellaichamy Swaminathan1, Satishkumar Meena2, Harika Varla2
1Department of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Apollo Hospitals, Chennai 600 035, Tamil Nadu. Correspondence to: Dr Venkateswaran Vellaichamy Swaminathan, Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Apollo Hospitals, 320, Padma Complex, Anna Salai, Teynampet, Chennai 600 035, Tamil Nadu. vsv.mezos97@gmail.com.
Insights
Hematopoietic stem cell transplantation (HSCT) offers a curative option for children with inborn errors of metabolism (IEM). Early HSCT is crucial for preventing end-organ damage and improving survival rates in pediatric patients.
Area of Science:
- Pediatric Hematology
- Metabolic Disorders
- Transplantation Medicine
Background:
- Inborn errors of metabolism (IEM) are a group of genetic disorders affecting metabolic pathways.
- Hematopoietic stem cell transplantation (HSCT) is a potential curative treatment for certain IEMs.
- Data on HSCT outcomes in pediatric IEM patients are essential for treatment planning.
Purpose of the Study:
- To present outcome data for hematopoietic stem cell transplantation (HSCT) in children diagnosed with inborn errors of metabolism (IEM).
- To evaluate the efficacy and survival rates of HSCT in this pediatric population.
Main Methods:
- Retrospective analysis of pediatric patients (up to 18 years) with IEM who underwent HSCT.
- Data collected between January 2002 and December 2020.
- Inclusion of various IEMs including mucopolysaccharidosis, Gaucher disease, X-linked adrenoleukodystrophy, metachromatic leukodystrophy, and Krabbe disease.
Main Results:
- 24 children with IEM underwent HSCT.
- Engraftment was achieved in 91% of patients.
- Overall survival was 72%, with progression-free survival at 68%.
- Specific survival rates varied by IEM type, with 100% progression-free survival for metachromatic leukodystrophy and Krabbe disease.
Conclusions:
- Hematopoietic stem cell transplantation (HSCT) is a viable curative treatment for children with inborn errors of metabolism (IEM).
- Performing HSCT at an early age is critical to prevent irreversible end-organ damage.
- The study highlights the importance of timely HSCT for improving long-term outcomes in pediatric IEM patients.
Objective:
We present outcome data on hematopoietic stem cell transplantation (HSCT) in children with inborn errors of metabolism (IEM).
Methods:
We retrospectively analyzed data on children up to 18 years of age, diagnosed with IEM, who underwent HSCT between January, 2002 and December, 2020.
Results:
24 children, (mucopolysaccharidosis - 13, Gaucher disease - 4, X-linked adrenoleukodystrophy - 4, metachromatic leukodystrophy - 2, Krabbe disease - 1) were included. Donors were matched family donors in 24%, matched unrelated donors in 34%, and haploidentical fathers in 42% of the transplants, with engraftment in 91% of children. Overall survival was 72% (55-100%) with a median follow-up of 76.5 (10-120 ) months, and progression-free survival of 68% (MPS-76%, X-ALD -60%, Gaucher disease - 50%, and 100% in MLD and Krabbe disease).
Conclusion:
HSCT is an available curative option, and early age at HSCT prevents end-organ damage.
More Related Videos
11:59Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
iPS Cell Differentiation
Inborn Errors of Metabolism
Regulation of Hematopoietic Stem Cells
Stem Cell Culture